CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ligand Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ligand Pharmaceuticals Inc
555 Heritage Drive, Suite 200
Phone: (858) 550-7500p:858 550-7500 JUPITER, FL  33458  United States Ticker: LGNDLGND
Business Summary
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board John W.Kozarich 73 3/1/2017 3/6/2003
President, Chief Operating Officer Matthew E.Korenberg 48 11/1/2022 8/6/2015
Chief Executive Officer, Director Todd C.Davis 62 12/5/2022 3/1/2007
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Vernalis Ltd (ADR) Granta Park Cambridge United Kingdom
Vernalis plc Granta Park Cambridge United Kingdom
Metabasis Therapeutics, Inc. 11119 North Torrey Pines Road La Jolla CA United States
4 additional Subsidiary records available in full report.

Business Names
Business Name
Allergan Ligand Retinoid Therapeutics, Inc.
Aramed Inc.
Cita NeuroPharmaceuticals Inc.
21 additional Business Names available in full report.

General Information
Number of Employees: 58 (As of 12/31/2023)
Outstanding Shares: 17,705,287 (As of 2/26/2024)
Shareholders: 339
Stock Exchange: NASD
Federal Tax Id: 770160744
Fax Number: (302) 636-5454
Email Address: INVESTORS@LIGAND.COM


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024